All In Biotech

Drug Trial Radar · NCT06076291

An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG1827 in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Sep 27, 2023

Primary completion

Mar 18, 2026

Study completion Mar 18, 2026

Sponsor

Sponsor type
Industry
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG1827 in subjects with Advanced Solid Tumors, refractory or resistant to standard therapy, or without available standard or curative therapy.

Conditions

  • Advanced Solid Tumors

Interventions

  • SG1827Drug

    PhaseⅠa will use an accelerated titration and Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.02mg/kg, 0.2mg/kg, 1mg/kg, 3mg/kg, 6mg/kg, 10mg/kg, and 15mg/kg by IV infusion. Accelerated titration (1 patient) will be only applied to the first cohort.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: Through study completion, an average of one year
  2. MTD/MAD/ RP2DTime frame: Through study completion, an average of one year

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • The Affiliated Hospital of USTC

    Hefei, Anhui, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Henan Cancer Hospital

    Zhenzhou, Henan, China

  • The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University

    Changsha, Hunan, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.